Cell permeable p18 recombinant proteins, polynucleotides encoding the same, and anticancer composition comprising the same
The present invention discloses cell permeable p18 recombinant proteins where a macromolecule transduction domain (MTD) is fused to a tumor suppressor p18. Also disclosed are polynucleotides encoding the cell permeable p18 recombinant proteins, an expression vector containing the cell permeable p18 recombinant protein, and a pharmaceutical composition for treating p18 deficiency or failure which contains the cell permeable p18 recombinant protein as an effective ingredient. The cell permeable p18 recombinant proteins of the present invention are capable of efficiently introducing a haploinsufficient tumor suppressor p18 into a cell, and thus, can activate cell signaling mechanisms involved in the activation of ATM and p53 that induce cell cycle arrest and apoptosis in response to DNA damage or oncogenic signals. Therefore, the cell permeable p18 recombinant proteins of the present invention can be effectively used as an anticancer agent.
Latest Procell Therapeutics Inc. Patents:
- Development of novel macromolecule transduction domain with improved cell permeability and method for using same
- Development of novel macromolecule transduction domain with improved cell permeability and method for using same
- Macromolecule transduction domains and methods for identification and uses thereof
- Development of Novel Macromolecule Transduction Domain with Improved Cell Permeability and Method for Using Same
- NOVEL MACROMOLECULE TRANSDUCTION DOMAINS AND METHODS FOR IDENTIFICATION AND USES THEREOF
The present application is a 35 U.S.C. §371 National Stage patent application of International patent application PCT/KR2008/005222, filed on Sep. 4, 2008, which claims priority to Korean patent application KR 10-2008-0059938, filed on Jun. 25, 2008 and U.S. provisional patent application 60/969,762, filed on Sep. 4, 2007.
TECHNICAL FIELDThe present invention relates to cell permeable p18 recombinant proteins in which a tumor suppressor p18 is fused to a macromolecule transduction domain (MTD), polynucleotides encoding the same, expression vectors for producing the same, and anticancer pharmaceutical compositions including the same as effective ingredients for treating p18 deficiency or failure.
BACKGROUND ARTA eukaryotic cell goes through a series of events in the cell cycle resulting in replication and proliferation. The cell cycle consists of four distinct phases: G1 phase which is a quiescent phase from the end of the previous M phase till the beginning of DNA synthesis; S phase when DNA replication occurs; G2 phase when significant protein synthesis occurs in preparation of cell mitosis (the G1, S and G2 phases being collectively known as an interphase); and M phase when nuclear division (i.e., chromosomes separate) and cytoplasmic division (i.e., cytokinesis) occur. As these events are repeated, cell replication and proliferation are accomplished.
Cell cycle check points are control mechanisms that ensure the fidelity of cell division in eukaryotic cells. These check points verify whether the process at each phase of the cell cycle has been properly completed before progression into the next phase. For example, if the cells are damaged or exposed to radiation, the cell cycle may be interrupted at three check points during the oncogenesis: the G1 check point for blocking the progress from the G1 phase to the S phase; the S check point for delaying the progress of the S phase; and the G2 check point for blocking the progress from the G2 phase to the M phase (Kastan, M. B. Nature 410: 766-7, 2001).
Such delicate regulation of the cell cycle is controlled by various regulatory molecules, the most important of which is cyclin-dependent kinase (CDK). CDKs couple with regulatory proteins called cyclins that are specifically expressed at each phase of the cell cycle to form functional units, resulting in the generation of various combinations of cyclin-CDK complexes specifically activated at each phase of the cell cycle. Upon receiving a pro-mitotic extracellular signal, the cell proceeds to the S phase. Specifically, the cyclin D-CDK2 or cyclin D-CDK6 complex is activated first, the cyclin E-CDK2 complex is next activated upon entering S phase, and then, cyclin A interacts with CDK2 to carry out the cell cycle progression during late G1 and early S phases.
As indicated above, cell cycle progression is regulated by the various cyclins and kinases interacting therewith, and the coupling with CDK inhibitory factors, such as CDK4 inhibitor (INK4) and CDK interacting protein/kinase inhibitory protein (CIP/KIP) family, plays an important role in cell cycle regulation (Balomenos, D. and Martinez, A. C. Immunol. Today 21: 551-5, 2000). Further, ataxia telangiectasia mutated (ATM), which is a serine/threonine protein kinase of the phosphatidylinositol 3-kinase related kinases (PIKK) family, has been found to control cell-cycle check points in response to DNA damage or oncogenic signals, thereby ensuring genomic integrity and stability. ATM is necessary for the phosphorylation and activation of downstream factors, such as p53, murine double minute 2 (MDM2) and BRCA1 (Lu, S. et al., Carcinogenesis 27: 848-55, 2006). For instance, if the cells receive an oncogenic signal, such as damage to the double-strand DNA, ATM activates target proteins that induce cell cycle arrest and apoptosis, resulting in the regulation of gene transcription and DNA repair (Abraham, R. T. Nat. Med. 11: 257-8, 2005).
It has been found that p18 relating to ATM acts as a tumor suppressor in mice and humans. p18 deficiency or failure increases susceptibility to cancer by suppressing apoptosis of cells with DNA damage or mutations, thereby leading to malignant transformation of cells (Abraham, R. T. Nat. Med. 11: 257-8, 2005). In previous studies using p18 knock out mice, p18 homozygous knock out mice caused embryonic lethality, while p18 heterozygous knock out mice showed high susceptibility to various tumors including liver cancer, breast cancer, lung cancer, and the like (Park, B. J. et al., Cell 120: 209-21, 2005). p18 is transported into the nucleus and activated in response to DNA damage, where an increase in p18 expression leads to the phosphorylation and activation of p53 (French, J. E. et al., Carcinogenesis 22: 99-106, 2001; Ide, F. et al., Am. J. Pathol. 163: 1729-33, 2003), which is another tumor suppressor that controls cell proliferation and death. In contrast, p18 depletion inhibits the expression of p53 (Park, B. J. et al., Cell 120: 209-21, 2005).
The tumor suppressor gene p18 is located on chromosome region 6p24-25, where a loss-of heterozygosity (LOH) region was found in lymphoma (Baumgartner, A. K. et al., Lab. Invest. 83: 1509-16, 2003). It has been suggested that LOH in this chromosome is responsible for the lower expression of p18. According to recent studies, reduced levels of endogenous p18 have generally and frequently been detected in various human cancer cell lines as well as primary tissues, suggesting that p18 is a rate-limiting factor in the mechanism for ATM-mediated p53 activation, as well as a haploinsufficient tumor suppressor (Park, B. J. et al., Cell 120: 209-21, 2005).
Based on the fact that p18 is a potent tumor suppressor which directly interacts with ATM to activate p53 in response to oncogenic signals such as DNA damage (Savitsky, K. et al., Hum. Mol. Genet. 4: 2025-32, 1995) and is an attractive target protein as a haploinsufficient tumor suppressor involved in the signaling pathway of cell-cycle checkpoints including ATM and p53 (Kastan, M. B. Nature 410: 766-7, 2001; Balomenos, D. and Martinez, A. C. Immunol. Today 21: 551-5, 2000; Abraham, R. T. Nat. Med. 11: 257-8, 2005; Park, B. J. et al., Cell 120: 209-21, 2005), the present inventors have endeavored to develop new anticancer agents.
Meanwhile, small molecules derived from synthetic compounds or natural compounds can be transported into the cells, whereas macromolecules, such as proteins, peptides, and nucleic acids, cannot. It is widely understood that macromolecules larger than 500 kDa are incapable of penetrating the plasma membrane, i.e., the lipid bilayer structure, of live cells. To overcome this problem, a macromolecule intracellular transduction technology (MITT) was developed (Jo et al., Nat. Biotech. 19: 929-33, 2001), which allows the delivery of therapeutically effective macromolecules into cells, making the development of new drugs using peptides, proteins and genetic materials possible. According to this method, if a target macromolecule is fused to a hydrophobic macromolecule transduction domain (MTD) and other cellular delivery regulators, synthesized, expressed, and purified in the form of a recombinant protein, it can penetrate the plasma membrane lipid bilayer of the cells, be accurately delivered to a target site, and then, effectively exhibit its therapeutic effect. Such MTDs facilitate the transport of many impermeable materials which are fused to peptides, proteins, DNA, RNA, synthetic compounds, and the like into the cells.
Accordingly, the inventors of the present invention have developed a method of mediating the transport of tumor suppressor p18 into the cells, where cell permeable p18 recombinant proteins are engineered by fusing a MTD to the tumor suppressor p18. Such cell permeable p18 recombinant proteins have been found to efficiently mediate the transport of tumor suppressor p18 into the cells in vivo as well as in vitro and can be used as anticancer agents for treating p18 deficiency or failure occurring in various human cancers.
DISCLOSURE Technical ProblemAccordingly, the objective of the present invention is to provide cell permeable p18 recombinant proteins effective for the treatment of p18 deficiency or failure occurring in various kinds of human cancers as an anticancer agent.
Technical SolutionOne aspect of the present invention relates to cell permeable p18 recombinant proteins capable of mediating the transport of a tumor suppressor p18 into a cell by fusing a macromolecule transduction domain (MTD) having cell permeability to the tumor suppressor protein.
Another aspect of the present invention relates to polynucleotides encoding the above cell permeable p18 recombinant proteins.
The present invention also relates to expression vectors containing the above polynucleotides, and transformants transformed with the above expression vectors.
Another aspect of the present invention relates to a method of producing cell permeable p18 recombinant proteins involving culturing the above transformants.
Another aspect of the present invention relates to a pharmaceutical composition including the above cell permeable p18 recombinant proteins as an effective ingredient for treating p18 deficiency or failure.
The present invention provides cell permeable p18 recombinant proteins (CP-p18) capable of mediating the transport of a tumor suppressor p18 into a cell in which the tumor suppressor p18 is fused to a macromolecule transduction domain and, thereby, imparted with cell permeability; and polynucleotides encoding each of the cell permeable p18 recombinant proteins.
The present invention is characterized in that a tumor suppressor p18 which is a macromolecule incapable of being introduced into a cell is fused to a specific macromolecule transduction domain (hereinafter, “MTD”) peptide so as to provide cell permeability, and thus, can be effectively transported into a cell. The MTD peptide may be fused to the N-terminus, the C-terminus, or both termini of the tumor suppressor p18.
The present invention relates to cell permeable p18 recombinant proteins that are engineered by fusing a tumor suppressor p18 to one of three MTD domains capable of mediating the transport of a macromolecule into a cell.
The term “cell permeable p18 recombinant protein” as used herein refers to a covalent bond complex bearing a MTD and a tumor suppressor protein p18, where they are functionally linked by genetic fusion or chemical coupling. Here, the term “genetic fusion” refers to a co-linear, covalent linkage of two or more proteins or fragments thereof via their individual peptide backbones, through genetic expression of a polynucleotide molecule encoding those proteins.
p18 is a tumor suppressor protein which directly interacts with ATM in response to oncogenic signals, such as DNA damage, for the activation of p53 which induces cell cycle arrest and apoptosis. p18 has an amino acid sequence represented by SEQ ID NO: 2, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 1. p18 functions as an important target protein in signal transduction pathways including ATM p53.
The amino acid sequence of the tumor suppressor p18, i.e., SEQ ID NO: 2, is composed of a N-terminal domain corresponding to amino acid residues 1-60, a S-terminal domain corresponding to amino acid residues 61-120, and a C-terminal domain corresponding to amino acid residues 121-168 (see
For the MTD capable of being fused to the tumor suppressor p18, cell permeable peptides having an amino acid sequence selected from the group consisting of SEQ ID NOS: 4, 6, 8, and 53 to 243 may be used. The MTD having one of the amino acid sequences represented by SEQ ID NOS: 4, 6, 8 and 53 to 243 is a cell permeable polypeptide which is capable of mediating the transport of a biologically active molecule, such as a polypeptide, a protein domain, or a full-length protein across the cell membrane. Suitable MTDs for the present invention include a hydrophobic region showing cell membrane targeting activity by forming a helix structure at a signal peptide which is composed of an N-terminal domain, a hydrophobic domain and a C-terminal domain containing a secreted protein cleavage site. These MTDs can directly penetrate the cell membrane without causing any cell damage, transport a target protein into a cell, and thus, allow the target protein to exhibit its desired function.
The MTDs having the amino acid sequences represented by SEQ ID NOS: 4, 6, 8, and 53 to 243 and capable of being fused to a tumor suppressor p18 according to the present invention are summarized in the following Tables 1a to 1l.
In some embodiments, the present invention may employ a kaposi fibroblast growth factor 4 (kFGF4)-derived MTD having the nucleotide sequence of SEQ ID NO: 3 and the amino acid sequence of SEQ ID NO: 4 (hereinafter, “MTD1”), a JO-101 MTD having the nucleotide sequence of SEQ ID NO: 5 and the amino acid sequence of SEQ ID NO: 6 which is a hypothetical protein derived from Theileria annulata (hereinafter, “MTD2”), and a JO-103 MTD having the nucleotide sequence of SEQ ID NO: 7 and the amino acid sequence of SEQ ID NO: 8 which belongs to member B of a human TMEM9 domain family (hereinafter, “MTD3”), as the MTD capable of mediating the transport of the tumor suppressor p18 into a cell.
The cell permeable p18 recombinant proteins according to the present invention have a structure where one of the three MTDs (kFGF4-derived MTD: MTD1, JO-101: MTD2, JO-103: MTD3) is fused to one terminus or both termini of a tumor suppressor protein p18, and a SV40 large T antigen-derived nuclear localization sequence (NLS) (nucleotide sequence of SEQ ID NO: 9, amino acid sequence of SEQ ID NO:10) and a histidine-tag (His-Tag) affinity domain for easy purification are fused to one terminus of the resulting construct.
In another embodiment, the present invention relates to the construction of three full-length forms and five truncated forms of a cell permeable p18 recombinant protein by using a kFGF4-derived MTD.
As used herein, the term “full-length form” refers to a construct including the entire N-, S-, and C-terminal domains of the tumor suppressor protein p18, while the term “truncated form” refers to a construct lacking any one or more of the N-, S-, and C-terminal domains thereof.
Referring to
1) HM1p18, where a kFGF4-derived MTD is fused to the N-terminus of a full-length p18,
2) Hp18M1, where a kFGF4-derived MTD is fused to the C-terminus of a full-length p18, and
3) HM1p18M1, where a kFGF4-derived MTD is fused to both termini of a full-length p18,
where a His-tag and a NLS derived from SV40 large T antigen are covalently coupled to the N-terminus of the above constructs.
As for the full-length forms of the cell permeable p18 recombinant protein as described above, HM1p18 has an amino acid sequence represented by SEQ ID NO: 26, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 25; Hp18M1 has an amino acid sequence represented by SEQ ID NO: 28, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 27; HM1p18M1 has an amino acid sequence represented by SEQ ID NO: 30, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 29.
Further, the truncated forms of the cell permeable p18 recombinant protein are as follows:
1) Hp18NM1, where a kFGF4-derived MTD is fused to the C-terminus of a p18 N-terminal domain fragment lacking S- and C-terminal domains,
2) Hp18SM1, where a kFGF4-derived MTD is fused to the C-terminus of a p18 S-terminal domain fragment lacking N- and C-terminal domains,
3) Hp18CM1, where a kFGF4-derived MTD is fused to C-terminus of a p18 C-terminal domain fragment lacking N- and S-terminal domains,
4) Hp18NSM1, where a kFGF4-derived MTD is fused to the C-terminus of a p18 N- and S-terminal domain fragment lacking a C-terminal domain, and
5) Hp18SCM1, where a kFGF4-derived MTD is fused to the C-terminus of a p18 S- and C-terminal domain fragment lacking an N-terminal domain,
where a His-tag and a NLS derived from SV40 large T antigen are covalently coupled to the N-terminus of the above constructs.
As for the truncated forms of the cell permeable p18 recombinant protein as described above, Hp18NM1 has an amino acid sequence represented by SEQ ID NO: 32, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 31; Hp18SM1 has an amino acid sequence represented by SEQ ID NO: 34, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 33; Hp18CM1 has an amino acid sequence represented by SEQ ID NO: 36, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 35; Hp18NSM1 has an amino acid sequence represented by SEQ ID NO: 38, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 37; Hp18SCM1 has an amino acid sequence represented by SEQ ID NO: 40, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 39.
In another embodiment, the present invention relates to the construction of three full-length forms of a cell permeable p18 recombinant protein by using a JO-101 MTD and a JO-103 MTD, respectively.
Referring to
1) HM2p18, where a JO-101 MTD is fused to the N-terminus of a full-length p18,
2) Hp18M2, where a JO-101 MTD is fused to the C-terminus of a full-length p18,
3) HM2p18M2, where a JO-101 MTD is fused to both termini of a full-length p18,
4) HM3p18, where a JO-103 MTD is fused to the N-terminus of a full-length p18,
5) Hp18M3, where a JO-103 MTD is fused to the C-terminus of a full-length p18, and
6) HM3p18M3, where a JO-103 MTD is fused to both termini of a full-length p18,
where a His-tag and a NLS derived from SV40 large T antigen are covalently coupled to the N-terminus of the above constructs.
As for the full-length forms of a cell permeable p18 recombinant protein as described above, HM2p18 has an amino acid sequence represented by SEQ ID NO: 42, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 41; Hp18M2 has an amino acid sequence represented by SEQ ID NO: 44, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 43; HM2p18M2 has an amino acid sequence represented by SEQ ID NO: 46, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 45; HM3p18 has an amino acid sequence represented by SEQ ID NO: 48, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 47; Hp18M3 has an amino acid sequence represented by SEQ ID NO: 50, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 49; and HM3p18M3 has an amino acid sequence represented by SEQ ID NO: 52, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 51.
As a control for the cell permeable p18 recombinant proteins, Hp18, where a full-length p18 is fused only to a nuclear localization sequence (NLS) derived from SV40 large T antigen and a histidine-tag (His-Tag) without any MTD, is constructed. The control protein has an amino acid sequence represented by SEQ ID NO: 24, while a polynucleotide encoding the same has a nucleotide sequence represented by SEQ ID NO: 23.
Further, the present invention provides an expression vector containing the polynucleotide encoding each of the cell permeable p18 recombinant proteins described above, and a transformant capable of producing each of the cell permeable p18 recombinant proteins at high levels, which is obtainable by transforming a host cell using the expression vector.
As used herein, the term “expression vector” is a vector capable of expressing a target protein or a target RNA in a suitable host cell. The nucleotide sequence of the present invention may be present in a vector in which the nucleotide sequence is operably linked to regulatory sequences capable of providing for the expression of the nucleotide sequence by a suitable host cell.
Within an expression vector, the term “operably linked” is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence. The term “regulatory sequence” is intended to include promoters, enhancers, and other expression control elements. Such operable linkage with the expression vector can be achieved by conventional gene recombination techniques known in the art, while site-directed DNA cleavage and linkage are carried out by using conventional enzymes known in the art.
The expression vectors suitable for the present invention may include plasmid vectors, cosmid vectors, bacteriophage vectors, viral vectors and the like, but are not limited thereto. The expression vectors for use in the present invention may contain a signal sequence or a leader sequence for membrane targeting or secretion, as well as regulatory sequences such as a promoter, an operator, an initiation codon, a termination codon, a polyadenylation signal, an enhancer and the like. The promoter may be a constitutive or an inducible promoter. Further, the expression vector may include one or more selectable marker genes for selecting the host cell containing the expression vector, and may further include a nucleotide sequence that enables the vector to replicate in the host cell in question.
The expression vector constructed according to the present invention may be exemplified by pHp18M1 where the polynucleotide encoding the recombinant protein Hp18M1 where a kFGF4-derived MTD is fused to the N-terminus of a full-length p18 is inserted into a cleavage site of NdeI restriction enzyme within the multiple cloning sites (MCS) of a pET-28a(+) vector.
In another embodiment, the polynucleotide of the present invention is cloned into a pET-28a(+) vector (NOVAGEN, USA) bearing a His-tag sequence so as to fuse six histidine residues to the N-terminus of the cell permeable p18 recombinant protein to allow easy purification.
Accordingly, the cell permeable p18 recombinant protein expressed in the above expression vector has a structure where one of a kFGF4-derived MTD, a JO-101 MTD and a JO-103 MTD is fused to the full-length or truncated p18, and a His-tag and NLS are linked to the N-terminus thereof.
The present invention further provides a transformant capable of producing each of the cell permeable p18 recombinant proteins at high levels which is obtainable by transforming a host cell using the expression vector. The host cell suitable for the present invention may be eukaryotic cells, such as E. coli. In one embodiment of the present invention, E. coli used as a host cell is transformed with the expression vector, for example, pHp18M1 containing the polynucleotide encoding the cell permeable recombinant protein Hp18M1 where a kFGF4-derived MTD is fused to the C-terminus of a full-length p18 according to the present invention so as to produce the cell permeable p18 recombinant protein at high levels. Methods for transforming bacterial cells are well known in the art, and include, but are not limited to, biochemical means such as transformation, transfection, conjugation, protoplast fusion, calcium phosphate-precipitation, and application of polycations such as diethylaminoethyl (DEAE) dextran, and mechanical means such as electroporation, direct microinjection, microprojectile bombardment, calcium phosphate (CaPO4) precipitation, calcium chloride (CaCl2) precipitation, PEG-mediated fusion and liposome-mediated method.
In some embodiments, the transformants obtained by transforming E. coli DH5α with the expression vector containing the cell permeable p18 recombinant protein Hp18M1 where a kFGF4-derived MTD is fused to the C-terminus of a full-length p18, the expression vector containing the cell permeable p18 recombinant protein HM2p18M2 where a JO-101 MTD is fused to the both termini thereof, and the expression vector containing the cell permeable p18 recombinant protein HM3p18 where a JO-103 MTD is fused to the N-terminus thereof, respectively, were deposited under accession numbers KCTC-110310BP, KCTC-110311BP and KCTC-11312BP, respectively, with the Korean Collection for Type Cultures (KCTC), Korea Research Institute of Bioscience and Biotechnology (KRIBB), 52, Oun-Dong, Yusong-Ku, Taejon 305-333, Republic of Korea. All deposits referred to herein were made on Apr. 12, 2008 in accordance with the Budapest Treaty, and all restrictions imposed by the depositor on the availability to the public of the deposited biological material will be irrevocably removed upon the granting of the patent.
The present invention provides a method of producing the cell permeable p18 recombinant proteins at high levels, which includes the step of culturing the above transformant.
The method of the present invention may be carried out by culturing the transformant in a suitable medium under suitable conditions for expressing a cell permeable p18 recombinant protein of the present invention in the expression vector introduced into the transformant. Methods for expressing a recombinant protein by culturing a transformant are well known in the art, and for example, may be carried out by inoculating a transformant in a suitable medium for growing the transformant, performing a subculture, transferring the same to a main culture medium, culturing under suitable conditions, for example, supplemented with a gene expression inducer, isopropyl-β-D-thiogalactoside (IPTG) and, thereby, inducing the expression of a recombinant protein. After the culture is completed, it is possible to recover a “substantially pure” recombinant protein from the culture solution. The term “substantially pure” means that the recombinant protein and polynucleotide encoding the same of the present invention are essentially free of other substances with which they may be found in nature or in vivo systems to the extent practical and appropriate for their intended use.
A recombinant protein of the present invention obtained as above may be isolated from the inside or outside (e.g., medium) of host cells, and purified as a substantially pure homogeneous polypeptide. The method for polypeptide isolation and purification is not limited to any specific method. In fact, any standard method may be used. For instance, chromatography, filters, ultrafiltration, salting out, solvent precipitation, solvent extraction, distillation, immunoprecipitation, SDS-polyacrylamide gel electrophoresis, isoelectric point electrophoresis, dialysis, and recrystallization may be appropriately selected and combined to isolate and purify the polypeptide. As for chromatography, affinity chromatography, ion-exchange chromatography, hydrophobic chromatography, gel filtration chromatography, reverse phase chromatography, adsorption chromatography, etc., for example, may be used (Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1982; Sambrook et al., Molecular Cloning: A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, 1989; Deutscher, M., Guide to Protein Purification Methods Enzymology vol. 182. Academic Press. Inc., San Diego, Calif., 1990).
Meanwhile, the recombinant protein expressed in the transformants according to the present invention can be classified into a soluble fraction and an insoluble fraction according to protein characteristics during the protein purification process. If the majority of the expressed recombinant proteins are present in the soluble fraction, the recombinant protein can be isolated and purified according to the method as described above. However, when the majority of the expressed recombinant proteins are present in the insoluble fraction, i.e., as inclusion bodies, the recombinant proteins are first solubilized by using polypeptide denaturing agents, e.g., urea, guanidine HCl, or detergents, and then, purified by performing a series of centrifugation, dialysis, electrophoresis and column chromatography. Since there is the risk of losing the recombinant protein's activity due to a structural modification caused by the polypeptide denaturing agent, the process of purifying the recombinant protein from the insoluble fraction requires desalting and refolding steps. That is, the desalting and refolding steps can be performed by dialysis and dilution with a solution that does not include a polypeptide denaturing agent or by centrifugation with a filter. Further, if a salt concentration of the solution used for the purification of a recombinant protein from a soluble fraction is relatively high, such desalting and refolding steps may be performed.
In some embodiments, it has been found that the cell permeable p18 recombinant protein of the present invention mostly exists in the insoluble fraction as an inclusion body. In order to purify the recombinant protein from the insoluble fraction, the insoluble fraction may be dissolved in a lysis buffer containing a non-ionic surfactant such as Triton X-100, subjected to ultrasonification, and then centrifuged to separate a precipitate. The separated precipitate may be dissolved in a buffer supplemented with a strong denaturing agent, such as urea, and centrifuged to separate the supernatant. The above separated supernatant is purified by means of a histidin-tagged protein purification kit and subjected to ultrafiltration, for example, by using an amicon filter for salt removal and protein refolding, thereby obtaining a purified recombinant protein of the present invention.
Further, the present invention provides an anticancer pharmaceutical composition comprising the cell permeable p18 recombinant protein as an effective ingredient for treating p18 deficiency or failure.
The cell permeable p18 recombinant proteins of the present invention can activate cell signaling mechanisms involved in the activation of ATM and p53 that induce cell cycle arrest and apoptosis in response to DNA damage or oncogenic signals by efficiently introducing a tumor suppressor protein p18 into a cell. Therefore, the cell permeable p18 recombinant proteins of the present invention can be effectively used as an anticancer agent for treating various kinds of human cancers.
The pharmaceutical composition comprising the recombinant protein of the present invention as an effective ingredient may further include pharmaceutically acceptable carriers suitable for oral administration or parenteral administration. As used herein, “pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drugs, drug stabilizers, gels, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, such like materials and combinations thereof, as would be known to one of ordinary skill in the art (Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, Pa., 1995). The carriers for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid and the like. In case of oral administration, the recombinant protein of the present invention can be formulated in the form of chewable tablets, buccal tablets, troches, capsules, elixir, suspensions, syrup, wafers or combination thereof by mixing with the carriers. Further, the carriers for parenteral administration may include water, suitable oil, saline, aqueous glucose, glycol and the like, and may further include stabilizers and preservatives. The stabilizers suitable for the present invention may include antioxidants such as sodium bisulfite, sodium sulfite and ascorbic acid. Suitable preservatives may include benzalconium chloride, methyl-paraben, propyl-paraben and chlorobutanol.
The pharmaceutical composition of the present invention may be formulated into various parenteral or oral administration forms. Representative examples of the parenteral formulation include those designed for administration by injection. For injection, the recombinant proteins of the present invention may be formulated in aqueous solutions, specifically in physiologically compatible buffers or physiological saline buffer. These injection formulations may be formulated by conventional methods using one or more dispersing agents, wetting agents and suspending agents. For oral administration, the proteins can be readily formulated by combining the proteins with pharmaceutically acceptable carriers well known in the art. Such carriers enable the proteins of the invention to be formulated as tablets, pills, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. Such oral solid formulations may include suitable excipients such as diluents (e.g., lactose, dextrose, sucrose, mannitol, sorbitol cellulose and/or glycin) and lubricants (e.g., colloidal silica, talc, stearic acid, magnesium stearate, calcium stearate, and/or polyethylene glycol). The tablets may include binders, such as aluminum silicate, starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP), and disintegrating agents, such as cross-linked polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. If desired, absorbents, coloring agents, flavoring agents and/or sweeteners may be added. The formulations can be prepared by mixing, granulating or coating according to conventional methods well-known in the art.
If necessary, the pharmaceutical compositions of the present invention may further include pharmaceutical additives, such as preservatives, antioxidants, emulsifiers, buffering agents and/or salts for regulating osmosis and other therapeutically effective materials, and can be formulated according to conventional methods known in the art.
In addition, the pharmaceutical composition of the present invention can be administered via oral routes or parenteral routes such as intravenously, subcutaneously, intranasally or intraperitoneally. The oral administration may include sublingual application. The parenteral administration may include drip infusion and injection such as subcutaneous injection, intramuscular injection, intravenous injection and introtumoral injection.
The total effective amount of the recombinant protein of the present invention can be administered to patients in a single dose or can be administered by a fractionated treatment protocol, in which multiple doses are administered over a more prolonged period of time. Although the amount of the recombinant protein or nucleic acid encoding the same in the pharmaceutical composition of the present invention may vary depending on the severity of diseases, the protein or the nucleic acid may be generally administered several times a day at an effective dose of 5 to 20 mg. However, a suitable dose of the recombinant protein in the pharmaceutical composition of the present invention may depend on many factors, such as age, body weight, health condition, sex, disease severity, diet and excretion of patients, as well as the route of administration and the number of treatments to be administered. In view of the above factors, any person skilled in the art may determine the effective dose of the recombinant protein as an anticancer agent for treating or preventing p18 deficiency or failure. The pharmaceutical composition of the present invention containing the recombinant protein has no special limitations on its formulation, administration route and/or administration mode insofar as it exhibits the effects of the present invention.
EXAMPLESThe following examples are provided to illustrate the embodiments of the present invention in more detail, but are by no means intended to limit its scope.
Example 1 Construction of Cell Permeable p18 Recombinant Proteins (CP-p18)<1-1> Construction of p18 Recombinant Proteins by Using kFGF4-Derived MTD
Three full-length forms and five truncated forms of a cell permeable p18 (CP-p18) recombinant protein were constructed by using a kFGF4-derived MTD (MTD1).
Referring to
Further, the truncated forms of a CP-p18 recombinant protein were as follows: 1) Hp18NM1, wherein a kFGF4-derived MTD is fused to the C-terminus of a p18 N-terminal domain fragment lacking S- and C-terminal domains; 2) Hp18SM1, wherein a kFGF4-derived MTD is fused to the C-terminus of a p18 S-terminal domain fragment lacking N- and C-terminal domains; 3) Hp18CM1, wherein a kFGF4-derived MTD is fused to C-terminus of a p18 C-terminal domain fragment lacking N- and S-terminal domains; 4) Hp18NSM1, wherein a kFGF4-derived MTD is fused to the C-terminus of a p18 N- and S-terminal domain fragment lacking a C-terminal domain; and 5) Hp18SCM1, wherein a kFGF4-derived MTD is fused to the C-terminus of a p18 S- and C-terminal domain fragment lacking an N-terminal domain, wherein a His-tag and a NLS derived from SV40 large T antigen are covalently coupled to the N-terminus of all constructs. In order to prepare the truncated CP-p18 recombinant proteins, PCR was carried out by using the oligonucleotides described in Table 1 as a primer set specific for each recombinant protein and a human p18 cDNA (SEQ ID NO: 1) as a template (
The PCR was performed in a 50 μl reaction mixture containing 100 ng of human p18 cDNA as a template, 0.2 mM dNTP mixture (dGTP, dATP, dTTP, and dCTP, each at 2 mM), 0.6 μM of each primer, 5 μl of 10×Taq buffer, 1 μl of Taq polymerase (TAKARA, Japan). The PCR was performed for 30 cycles at 94° C. for 45 seconds, at 57° C. for 45 seconds and at 72° C. for 45 seconds after the initial denaturation of 94° C. for 3 minutes, followed by the final extension at 72° C. for 4 minutes. After the PCR was completed, the amplified PCR product was digested with restriction enzyme NdeI and loaded onto a 1.0% agarose gel and fractionated. As shown in
The DNA band of expected size was excised from the gel, eluted, and purified by using a QIAquick™ Gel extraction kit (QIAGEN, USA). The eluted DNA was precipitated with ethanol and resuspended in 6 μl of distilled water for ligation. As shown in
As shown in
A pET-28(+)a vector (NOVAGEN, Madison, WI) bearing a histidine-tag and a T7 promoter was digested with a restriction enzyme NdeI (Enzynomics, Korea). The pGEM-T Easy vector fragments containing the CP-p18 recombinant fragment and pET-28(+)a vector fragment were purified by using a QIAquick™ Gel extraction kit. Each of the pGEM-T Easy vector fragments was cloned into the pre-treated pET-28a(+) with a T4 ligase at 16° C. for 12 hours, followed by transformation of E. coli DH5α competent cells with the resulting pET-28a(+) vector (
After the clones were treated with the restriction enzyme NdeI (Enzynomics, Korea) and subjected to 0.8% agarose gel electrophoresis, it was verified that DNA fragments of about 0.6 kb for the full-length form and about 0.2-0.4 kb for the truncated forms and vector fragments of about 5 kb were detected, confirming the cloning of the insert DNA of CP-p18 recombinant construct into pET-28a(+) vector, as shown in
The successfully cloned expression vectors for expressing cell permeable p18 recombinant proteins were designated pHp18, pHM1p18, pHp18M1, pHM1p18M1, pHp18NM1, pHp18SM1, pHp18CM1, pHp18NSM1, and pHp18SCM1, respectively. Among them, the E. coli transformant DH5α/Hp18M1 obtained by transforming E. coli DH5α with the expression vector pHp18M1 was deposited on Apr. 12, 2008 in accordance with the Budapest Treaty under accession number KCTC-110310BP with the Korean Collection for Type Cultures (KCTC), Korea Research Institute of Bioscience and Biotechnology (KRIBB), 52, Oun-Dong, Yusong-Ku, Taejon 305-333, Republic of Korea.
<1-2> Construction of p18 Recombinant Proteins by Using JO-101 MTD and JO-103 MTD
In order to construct a cell permeable p18 recombinant protein by using a JO-101 MTD (MTD2) and a JO-103 MTD (MTD3), three full-length forms of a CP-p18 recombinant construct for each MTD were constructed.
Referring to
Further, the full-length forms of a CP-p18 recombinant construct fused to a JO-103 MTD were as follows: 1) HM3p18, where a JO-103 MTD is fused to the N-terminus of a full-length p18; 2) Hp18M3, where a JO-103 MTD is fused to the C-terminus of a full-length p18; and 3) HM3p18M3, where a JO-103 MTD is fused to both termini of a full-length p18, where a His-tag and a NLS derived from SV40 large T antigen are covalently coupled to the N-terminus of the above constructs. In order to prepare the full-length CP-p18 recombinant proteins, PCR was carried out according to the same method as described in section <1-1> of Example 1 above. The forward and reverse primers for amplifying HM3p18 have nucleotide sequences represented by SEQ ID NOS: 21 and 12, respectively, while those for amplifying Hp18M3 have nucleotide sequences represented by SEQ ID NOS: 11 and 22, respectively and those for amplifying HM3p18M3 have nucleotide sequences represented by SEQ ID NOS: 21 and 22, respectively.
Each of the PCR amplified DNA fragments was subcloned into a pGEM-T Easy vector, followed by cloning into a pET-28(+)a vector according to the same method as described in section <1-1> of Example 1 above, to thereby obtain expression vectors for expressing cell permeable p18 recombinant proteins. The successful insertion of the recombinant fragment into the pGEM-T Easy and pET-28(+)a vectors is confirmed in
The thus obtained expression vectors for expressing cell permeable p18 recombinant proteins were designated pHM2p18, pHp18M2, pHM2p18M2, pHM3p18, pHp18M3, and pHM3p18M3, respectively. Among them, the E. coli transformants DH5α/HM2p18M2 and DH5α/HM3p18 obtained by transforming E. coli DH5α with each of the expression vectors pHM2p18M2 and pHM3p18 were deposited on Apr. 12, 2008 in accordance with the Budapest Treaty under accession numbers KCTC-110311BP and KCTC-11312BP, respectively, with the Korean Collection for Type Cultures (KCTC), Korea Research Institute of Bioscience and Biotechnology (KRIBB), 52, Oun-Dong, Yusong-Ku, Taej on 305-333, Republic of Korea.
The oligonucleotides as a forward and reverse primer set specific for each recombinant protein are summarized in Table 2 below.
<2-1> Selection of Optimal Bacterial Strains
To select the optimal bacterial strain for the expression of cell permeable p18 recombinant proteins prepared in Example 1 above, the following experiments were carried out in E. coli BL21(DE3), BL21-Gold(DE3), BL21-CodonPlus(DE3) and BL21-Gold(DE3) pLysS strains (STRATAGENE, USA), all of which contain the LacI promoter.
First, each of the expression vectors pHM1p18, pHp18M1, and pHp18 (control) was transformed into E. coli BL21(DE3), BL21-Gold(DE3), BL21-CodonPlus(DE3) and BL21-Gold(DE3) pLysS strains, respectively, according to the heat shock method, followed by culturing in an LB medium containing 50 μg/ml of kanamycin. After that, the cells transformed with the recombinant protein encoding gene were grown in 1 ml of LB medium at 37° C. overnight, followed by culturing at 37° C. in 100 ml of LB medium with vigorous shaking until the optical density 600 (OD600) reached 0.5. IPTG (isopropyl-β-D-thiogalactoside) was then added thereto at a final concentration of 0.65 mM to induce the expression of the CP-p18 recombinant proteins. Protein induction was prolonged for 3 hours at 37° C. The E. coli culture solutions were harvested by centrifugation at 4° C., 7,000×g for 20 minutes, resuspended in a lysis buffer (100 mM NaH2PO4, 10 mM Tris-HCl, 8 M urea, pH 8.0), and subjected to ultrasonication on ice using a sonicator equipped with a probe. The cell lysates were centrifuged at 14,000×g for 15 minutes, so as to separate the insoluble fraction from the soluble fraction. The thus obtained soluble and insoluble fractions of CP-p18 recombinant proteins expressed in the E. coli strain with IPTG were loaded on a SDS-PAGE gel.
As shown in
<2-2> Expression of Recombinant Proteins
Each of the expression vectors pHM1p18, pHp18M1, and pHp18 (control) was transformed into E. coli BL21-CodonPlus(DE3), selected as the optimal strain in section <2-1> of Example 2 above, according to the heat shock method, followed by culturing in an LB medium containing 50 μg/ml of kanamycin. After that, the cells transformed with the recombinant protein encoding gene were grown in 25 ml of LB medium at 37° C. overnight, followed by culturing at 37° C. in 1 l of LB medium with vigorous shaking until the optical density 600 (OD600) reached 0.5. IPTG was then added thereto at a final concentration of 0.65 mM to induce the expression of the CP-p18 recombinant proteins. Protein induction was prolonged for 3 hours at 37° C. The E. coli culture solutions were harvested by centrifugation at 4° C., 7,000×g for 20 minutes, resuspended in a lysis buffer (100 mM NaH2PO4, 10 mM Tris-HCl, 8 M urea, pH 8.0), and subjected to ultrasonication on ice using a sonicator equipped with a probe. The cell lysates were centrifuged at 14,000×g for 15 minutes, so as to separate the insoluble fraction from the soluble fraction. The thus obtained soluble and insoluble fractions of CP-p18 recombinant proteins expressed in the E. coli strain with IPTG were loaded on a SDS-PAGE gel.
As shown in
The inducible expression of cell permeable p18 recombinant proteins in an E. coli system leads to the formation of insoluble aggregates, which are known as inclusion bodies. To completely solubilize these inclusion bodies, all of the above expressed proteins were denatured by dissolving them in 8 M urea used as a strong denaturing agent.
First, the BL21 CodonPlus(DE3) strains transformed with each of the expression vectors pHp18, pHM1p18, pHp18M1, pHM2p18, pHp18M2, pHM2p18M2, pHM3p18, pHp18M3, and pHM3p18M3 were cultured in 1 l of an LB medium as described in Example 2. Each culture solution was harvested by centrifugation, gently resuspended in 20 ml of a lysis buffer (100 mM NaH2PO4, 10 mM Tris-HCl, 8 M urea, pH 8.0) without forming bubbles, and subjected to ultrasonication on ice using a sonicator equipped with a microtip. The cells were intermittently sonicated for 30 seconds, followed by cooling for 10 seconds, while setting the power to 25% of the maximum power. The total sonication time was 5 minutes. The cell lysates were centrifuged at 3,000×g for 25 minutes, so as to separate the supernatant and the cellular debris pellet. The supernatant was loaded onto a Ni-NTA agarose resin where nitrilotriacetic acid agarose was charged with nickel (Ni). The Ni-NTA agarose resin was equilibrated with the lysis buffer. The supernatant was allowed to absorb onto the resin by gently shaking (using a rotary shaker) at 4° C. for 8 hours or more. The resin absorbed with the inclusion bodies containing the recombinant protein was centrifuged at 4° C., 1,000×g for 5 minutes, to remove the reaction solution and washed with a washing buffer (100 mM NaH2PO4, 10 mM Tris-HCl, 8 M urea, pH 6.3) five times to remove nonspecific absorbed materials. After washing, the proteins absorbed to the resin were eluted with an elution buffer (100 mM NaH2PO4, Tris-HCl, 8 M urea, pH 4.0) for 2 hours or 8 hours. The eluted proteins were analyzed with 12% SDS-PAGE gel electrophoresis, stained with Coomassie Brilliant Blue R by gently shaking, and destained with a destaining solution.
According to the results shown in
Since the cell permeable p18 recombinant proteins of the present invention purified from the insoluble fraction as described in Example 3 above were denatured by a strong denaturing agent, such as 8 M urea, the denatured proteins must be converted into an active form by a refolding process, as follows.
First, the purified recombinant proteins were subjected to a refolding process by dialyzing them against a refolding buffer (0.55 M guanidine HCl, 0.44 M L-arginine, 50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 100 mM NDSB, 2 mM glutathione oxidized, and 0.2 mM glutathione reduced) at 4° C. for 24 hours, thereby removing the denaturing agent. All of the refolded recombinant proteins were dialyzed against a cell culture medium DMEM (Dulbecco's Modified Eagle Medium) by using a dialysis bag (Snakeskin pleated, PIERCE) at 4° C. for 8 hours. The medium was replaced with fresh DMEM every 3 hours.
In order to quantitatively determine the cell permeability of the CP-p18 recombinant proteins refolded into their active form above, they were labeled with FITC (fluorescein-5-isothiocyanate, MOLECULAR PROBE). The recombinant protein (2 to 20 mg) was mixed with 1 μl of FITC at a concentration of 333 mg/ml and reacted in a dark room at room temperature for 1 hour by gentle stirring. The reaction solution was subjected to a dialysis against DMEM at 4□ for 1 day until the unreacted FITC was completely removed, thereby obtaining FITC-conjugated recombinant proteins. The thus obtained FITC-conjugated recombinant proteins were subjected to a Bradford protein assay to measure the protein concentration. As a result, each of the FITC-conjugated recombinant proteins was measured to have a concentration of about 1 μg/μl.
Example 5 Determination of Cell Permeability<5-1> Flow Cytometry
In order to quantitatively determine the cell permeability of the CP-p18 recombinant proteins according to the present invention, RAW 264.7 cells derived from mouse macrophage were incubated with 10 μM of each of the FITC-conjugated recombinant proteins prepared above for 1 hour at 37°. The RAW 264.7 cells were maintained in DMEM supplemented with 10% fetal bovine serum and 5% penicillin/streptomycin (500 mg/ml) and incubated at 37° in a humidified atmosphere of 5% CO2 in air. After the incubation, the cells were treated with trypsin/EDTA (T/E, INVITROGEN, Carlsbad, CA) to remove cell surface bound proteins, washed with cold PBS three times, and then, subjected to flow cytometry analysis by using a CellQuest™ Pro software program of the FACS (fluorescence-activated cell sorting) Calibur system (Beckton-Dickinson).
<5-2> Confocal Laser Scanning Microscope Analysis I
To visualize the intracellular localization of human p18 proteins delivered into a cell, NIH 3T3 cells were treated for 1 hour without (cell only) or with FITC (FITC only), or 10 μM FITC-conjugated recombinant proteins lacking kFGF4-derived MTD (Hp18) or 10 μM FITC-conjugated recombinant proteins fused to a kFGF4-derived MTD (HM1p18, Hp18M1), and visualized by confocal laser scanning microscopy. The NIH3T3 cells were maintained in DMEM supplemented with 10% fetal bovine serum, 5% penicillin/streptomycin (500 mg/ml) in 5% CO2 at 37°. In order to preserve the FITC fluorescence of the recombinant protein, the glass slide was fixed in 10 μl of a mounting medium for 15 minutes before the observation. For a direct detection of FITC-conjugated recombinant proteins that were internalized, the cells were washed with PBS three times and counterstained with a nuclear fluorescent stain solution, propidium iodide (PI, SIGMA ALDRICH, St. Louis, MO). The intracellular distribution of the fluorescence was determined at the middle of a single cell analyzed by a confocal laser scanning microscope using a normaski filter.
As shown in
<5-3> Confocal Laser Scanning Microscope Analysis II
In order to examine whether the cell permeable p18 recombinant proteins according to the present invention exhibit cell permeability with respect to a tissue, the following experiment was performed.
In this experiment, 7-week old MHC (major histocompatibility complex)-deficient Balb/c nu/nu mice (Central Lab. Animal Inc., Seoul) were used. The mice were subcutaneously injected with a human colon cancer cell line, HCT-116 cells (1×107) (Korean Cell Line Bank) on their right leg by using a syringe (omnican, Germany, B. BRAUN), so as to induce tumor formation. Meanwhile, Hp18M1 where a kFGF4-derived MTD (MTD1) was fused to its C-terminus, HM2p18M2 where a JO-101 MTD (MTD2) was fused to both termini thereof, HM3p18 where a JO-103 MTD (MTD3) was fused to its N-terminus, and Hp18 not being fused to a MTD were labeled with FITC. The tumor-bearing mice were administered with 300 μg of each of the FITC-conjugated recombinant proteins via intraperitoneal injection. Two hours later, the mice were sacrificed, and various tissue samples were extracted from the liver, kidney, spleen, lung, heart, brain, and tumor. The extracted tissues were embedded in an OCT compound, freezed, and then sectioned with a microtome to have a thickness of 14 tμm. The tissue specimens were mounted on a glass slide and observed with a confocal laser scanning microscope. In order to preserve the FITC fluorescence of the recombinant protein, the glass slide was fixed in 10 μl of a mounting medium for 15 minutes before the observation.
As illustrated in
<6-1> Western Blot Analysis
To evaluate the in vivo function of the cell permeable p18 recombinant proteins according to the present invention, a Western blot analysis was performed as follows. HCT-116 cells, a human colon cancer cell line used in this experiment, were purchased from Korean Cell Line Bank (Seoul, Republic of Korea). HCT-116 cells were maintained in a RPMI 1640 medium (L-glutamine 300 mg/f, 25 mM HEPES, 25 mM NaHCO3 89.3%, heat-inactivated fetal bovine serum 9.8%, streptomycin/penicillin 0.9%) in a 5% CO2 incubator at 37° C. After 2 ml of the RPMI 1640 medium was added to each well of a 6-well plate, HCT-116 cells were inoculated thereto, grown at 37° C. for 1 day, and then, further cultured for another day in the absence of serum. After removing the medium, the HCT-116 cells were washed with cold PBS (phosphate-buffered saline) and treated with each of HM1p18 where kFGF4-derived MTD was fused to its N-terminus, Hp18M1 where kFGF4-derived MTD was fused to its C-terminus, and Hp18 not being fused to a MTD at a concentration of 10 μM, 10 μM, and 20 μM, respectively. The cells treated with the recombinant proteins were reacted in a 5% CO2 incubator at 37° C. for 4 hours so as to induce the expression of p21, or for 1 hour so as to induce the phosphorylation of p53, ATM, MEK, ERK and Rb. After the reaction was completed, the cells were resuspended in 200 μl of a lysis buffer (20 mM HEPES, pH 7.2, 1% Triton-X, 10% glycerol) and subjected to ultrasonication on ice for 30 minutes, to thereby obtain a cell lysate. The cell lysate was centrifuged at 12,000 rpm for 20 minutes at 4° C. to separate the supernatant. The thus obtained supernatant was subjected to a Bradford protein assay to quantitatively measure the protein concentration, and stored at −80° C. until use.
For Western blot analysis, p21Waf1/Cip1 (21 kDa,CELL SIGNALING TECHNOLOGY), phospho-p53 (Ser15, 53 kDa, CELL SIGNALING TECHNOLOGY), phospho-ATM (Ser1981, 350 kDa, SANTA CRUZ BIOTECHNOLOGY), phospho-MEK1/2 (Ser217/221, 45 kDa, CELL SIGNALING TECHNOLOGY), phospho-Erk (Thr202/Tyr204, 42/44 kDa, CELL SIGNALING TECHNOLOGY), and phospho-Rb (Ser No.807/811, 110 kDa, Santa Cruz Biotechnology) were used as primary antibodies, and goat anti-mouse IgG-HRP (Santa Cruz Biotechnology) and goat anti-rabbit IgG-HRP (SANTA CRUZ BIOTECHNOLOGY) were used as secondary antibodies. The supernatant was applied to a 12% sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) at 100 V and transferred onto a PDVF membrane at 70 V for 2 hours. In order to prevent the nonspecific interaction between blotted proteins and unrelated antibodies, the PVDF membrane was blocked with 5% non-fat dry milk in TBS/T (10 mM Tris-C1, 150 mM NaCl, 0.05% Tween 20, pH 8.0) for 1 hour, followed by incubating with each of the primary antibodies for 1 hour at 4°. The membrane was washed with TBS/T five times and incubated with the secondary antibody for 1 hour at room temperature. After washing with TBS/T five times, the membrane was stained using an ECL (enhanced chemiluminescence) detection system (GE Healthcare Amersham UK) to visualize the antigen/antibody interaction.
As shown in
Meanwhile, the Western blot analysis was conducted for the JO-101 MTD (MTD2) fused recombinant proteins (HM2p18, Hp18M2 and HM2p18M2), JO-103 MTD (MTD3) fused recombinant proteins (HM3p18, Hp18M3 and HM3p18M3), and the control recombinant protein not being fused to a MTD (Hp18) according to the same method as described above.
Referring to the results shown in
<6-2> Cellular DNA Content Analysis
In order to examine the in vivo function of the cell permeable p18 recombinant proteins according to the present invention, the apoptosis-inducing effect of the recombinant protein was examined by cellular DNA content analysis as follows.
HCT-116 cells (Korean Cell Line Bank), a human colon cancer cell line, were cultured in a RPMI 1640 medium (L-glutamine 300 mg/l, 25 mM HEPES, 25 mM NaHCO3 89.3%, heat-inactivated fetal bovine serum 9.8%, streptomycin/penicillin 0.9%) in a 5% CO2 incubator at 37° C. After 2 ml of the RPMI 1640 medium was added to each well of a 6-well plate, the HCT-116 cells cultured above were inoculated thereto, and grown at 37° C. for 1 day. Each of the HM1p18 and Hp18M1, all of which contain a kFGF4-derived MTD (MTD1) fused thereto, HM2p18M2 to which JO-101 MTD (MTD2) was fused, HM3p18 to which JO-103 MTD (MTD3) was fused, and Hp18 not being fused to a MTD was added to each well at a concentration of 20 μM, followed by culturing them in a serum-free medium for 1 hour. After washing the well plate with cold PBS twice, 2 ml of the RPMI 1640 medium was added to each well, and the well plate was further incubated for 0, 2, 4, and 8 hours, respectively. After that, the cells were washed with cold PBS twice, suspended in 200 of PBS, and gently soaked in 4 ml of 70% ethanol. The thus obtained cell suspension was kept on ice for 45 minutes and stored at −20° C. for 1 day. The cell suspension was treated with PI (40 μg/ml) and RNase A (100 μg/ml) and subjected to flow cytometry analysis to quantify the degree of apoptosis induced.
According to the results shown in
<6-3> Analysis of the Apoptosis-Inducing Effect Using Annexin-V
In order to examine the in vivo function of the cell permeable p18 recombinant proteins according to the present invention, the apoptosis-inducing effect of the recombinant protein was examined by an Annexin-V assay as follows.
HCT-116 cells (Korean Cell Line Bank), a human colon cancer cell line, were cultured in a RPMI 1640 medium (L-glutamine 300 mg/l, 25 mM HEPES, 25 mM NaHCO3 89.3%, heat-inactivated fetal bovine serum 9.8%, streptomycin/penicillin 0.9%) in a 5% CO2 incubator at 37° C. After 2 ml of the RPMI 1640 medium was added to each well of a 6-well plate, the HCT-116 cells cultured above were inoculated thereto, and grown at 37° C. for 1 day. Each of HM3p18 to which JO-103 MTD (MTD3) was fused and Hp18 not being fused to a MTD was added to each well at a concentration of 20 μM, followed by culturing them in a serum-free medium for 1 hour. After that, the cells were washed with cold PBS twice, and suspended in 1 ml of a binding buffer (1×) at a concentration of 1×106 cells/ml. Subsequently, 100 ml of the cell suspension was transferred to an EP-tube, 5 ml of Annexin-V and 5 ml of PI were added thereto, and then, the EP-tube was reacted at room temperature for 15 minutes. After the reaction was completed, 400 ml of the binding buffer (1×) was added to the EP-tube, and the cells were subjected to a flow cytometry analysis to quantify the degree of apoptosis induced.
Referring to the results shown in
<7-1> Anticancer Effect During Administration
In order to examine the in vivo function of the cell permeable p18 recombinant proteins according to the present invention, the anticancer effect of the recombinant protein was investigated by using an animal model as follows.
In this experiment, 7-week old MHC-deficient Balb/c nu/nu mice (Central Lab. Animal Inc., Seoul) were employed. The mice were subcutaneously injected with a human colon cancer cell line, HCT-116 cells (1×107) (Korean Cell Line Bank) on their right leg by using a syringe (omnican, Germany, B. BRAUN), so as to induce tumor formation. Twenty four mice were subdivided into 4 groups of 6 mice each. From the day when the tumor size (width2×length/2) measured by using a vernier caliper reached 100 mm3, 300 μg of each of the cell permeable p18 recombinant proteins HM1p18 (Group 3, 1 μg/μl) and Hp18M1 (Group 4, 1 μl/μg), all of which contain a kFGF4-derived MTD fused thereto, was administered daily to the mice for 21 days via intraperitoneal injection. As a control, 300 μl of each of the vehicle (RPMI 1640 medium, Group 1) and Hp18 not being fused to a MTD (Group 2) was administered to the mice via intraperitoneal injection for 21 days. After the injection was completed, the tumor size and body weight of the mouse in each group were measured, where the results are shown in
Referring to the results shown in
<7-2> Anticancer Effect after Administration
In order to examine the durability of the in vivo anticancer effect of the cell permeable p18 recombinant proteins (HM1p18, Hp18M1) after administration, each of the recombinant proteins was administered to the mice for 21 days according to the same method as described in section <7-1> of Example 7 above. After the administration was terminated, 2 mice were selected from each group, and their tumor size was observed for 7 days.
According to the results shown in
<8-1> Anticancer Effect During Administration
In order to examine the in vivo function of the cell permeable p18 recombinant proteins according to the present invention, HCT-116 cells (1×107) were subcutaneously injected to the right leg of a 5-week old MHC-deficient Balb/c nu/nu mice by using a syringe according to the same method as described in Example 7 above. Fifteen mice were subdivided into 3 groups of 5 mice. The mice bearing a tumor of 70 to 80 mm3 in size (width2×length/2) were selected by using a vernier caliper. Each of the cell permeable p18 recombinant protein (HM3p18, 300 μg) to which JO-103 MTD was fused, a vehicle (RPMI 1640 medium, 300 μl) and the recombinant protein Hp18 not being fused to a MTD (300 μg) as a control was daily administered to the tumor-bearing mice via intravenous injection for 14 days.
According to the results shown in
<8-2> Anticancer Effect after Administration
In order to examine the durability of the in vivo anticancer effect of the cell permeable p18 recombinant proteins (HM3p18) after administration, each of the recombinant proteins was administered to the mice for 14 days according to the same method as described in section <8-1> of Example 8. After the administration was terminated, 2 mice were selected from each group and their tumor size was observed for 14 days.
Referring to the results shown in
<9-1> Anticancer Effect During Administration
In order to examine the in vivo function of the cell permeable p18 recombinant proteins according to the present invention, HCT-116 cells (1×107) were subcutaneously injected to the right leg of a 5-week old MHC-deficient Balb/c nu/nu mice by using a syringe according to the same method as described in Example 7 above. Twenty five mice were subdivided into 5 groups of 5 mice. The mice bearing a tumor of 90 to 100 mm3 in size (width2×length/2) were selected by using a vernier caliper. Each of the cell permeable p18 recombinant proteins Hp18M1 (300 μg) to which kFGF-derived MTD was fused, HM2p18M2 (300 μg) to which JO-101 MTD was fused, HM3p18 (300 μg) to which JO-103 MTD was fused, Hp18 not being fused to a MTD (300 μg), and a vehicle (RPMI 1640 medium, 300 μl) as a control was administered to the tumor-bearing mice via intratumoral injection.
According to the results shown in
<9-2> Anticancer Effect after Administration
In order to examine the durability of in vivo anticancer effect of the cell permeable p18 recombinant proteins (Hp18M1, HM2p18M2, HM3p18) after administration, each of the recombinant proteins was administered to the mice for 14 days according to the same method as described in section <9-1> of Example 9. After the administration was terminated, two mice were selected from each group, and their tumor size was observed for 14 days.
According to the results shown in
In order to examine the effect of inducing apoptosis in tumor tissues after the administration of the cell permeable p18 recombinant proteins, a histological analysis using hematoxylin & eosin staining was performed on the same mouse model as used in Example 8.
In particular, the cell permeable p18 recombinant protein (HM3p18), vehicle, and Hp18 (control) were administered to the mice subdivided into three groups (5 mice per group) via intravenous injection for 14 days, respectively, according to the same method as described in Example 8. After three mice were selected from each group and sacrificed, tumor tissue samples were extracted therefrom. The other two mice remaining in each group had undergone further observation for 14 days after the administration was terminated, and then, tumor tissue samples were extracted therefrom. Each tumor tissue extracted above was fixed in formalin and embedded in paraffin melted at 62° C. in an embedding center, to thereby prepare a paraffin block. The paraffin block was sliced with a microtome to have a thickness of 4 μm, where the slices were mounted on a slide glass and treated with xylene for 5 minutes three times to remove paraffin. Next, the glass slide was hydrated by successively treating with 100%, 95%, 90%, 80% and 70% ethanol each for 2 minutes, washed with water for 5 minutes, and then, stained with hematoxylin & eosin. Finally, the glass slide was dehydrated by successively treating with 70%, 80%, 90%, 95%, and 100% ethanol each for 10 seconds and dewaxed by treating with xylene twice each for 3 minutes. And then, the glass slide was sealed with Canada balsam as a mounting medium and observed with an optical microscope.
Referring to the results shown in
In order to examine the effect of inducing apoptosis in tumor tissues after the administration of the cell permeable p18 recombinant proteins, a histological analysis using hematoxylin & eosin staining was performed on the same mouse model as used in Example 9.
The hematoxylin & eosin staining was performed according to the same method as described in Example 10, except that each of the cell permeable p18 recombinant proteins (Hp18M1, HM2p18M2, HM3p18), vehicle, and Hp18 (control) was administered to the mice subdivided into five groups (5 mice per group) via intratumoral injection for 14 days according to the same method as described in Example 9, and tumor tissue samples were extracted from a mouse in each group.
According to the results shown in
In order to examine the effect of inducing apoptosis in tumor tissues after the administration of the cell permeable p18 recombinant proteins, a TUNEL assay was performed by using the same mouse model as described in Example 8.
In particular, each of the cell permeable p18 recombinant protein (HM3p18), vehicle, and Hp18 (control) was administered to the mice subdivided into three groups (5 mice per group) via intravenous injection for 14 days according to the same method as described in Example 8. After three mice were selected from each group and sacrificed, tumor tissue samples were extracted therefrom. The other two mice remaining in each group had undergone further observation for 14 days after the administration was terminated, and then, tumor tissue samples were extracted therefrom. The tissue specimen was prepared by using the extracted tumor tissue according to the same method as described in Example 10 and mounted on a glass slide. The glass slide was treated with xylene for 5 minutes three times, to thereby remove paraffin. It was then successively treated with 100%, 95%, 90%, 80%, and 70% ethanol each for 2 minutes so as to dehydrate the tumor tissue, followed by incubation in PBS for 5 minutes. The glass slide was treated with 0.1% Trition® X-100 dissolved in a 0.1% sodium citrate solution for 8 minutes, and washed with PBS twice for 2 minutes. After a drop of TUNEL reaction buffer (50 μl, ROCHE, USA) was added to the glass slide, the glass slide was incubated in a humidified incubator at 37□ for 1 hour, washed with PBS three times, and then, observed with a fluorescence microscope.
Referring to the results shown in
In order to examine the effect of inducing apoptosis in tumor tissues after the administration of the cell permeable p18 recombinant proteins, the following histochemical assay was performed by using an ApopTag Peroxidase in situ Apoptosis Detection Kit (CHEMICON, S7100).
In particular, each of the cell permeable p18 recombinant protein (HM3p18), vehicle, and Hp18 (control) was administered to the mice subdivided into three groups (5 mice per group) via intravenous injection for 14 days according to the same method as described in Example 8. After three mice were selected from each group and sacrificed, tumor tissue was extracted therefrom. The other two mice remaining in each group had undergone further observation for 14 days after the administration was terminated, and then, tumor tissue samples were extracted therefrom. The tissue specimen was prepared by using the extracted tumor tissue according to the same method as described in Example 10 and mounted on a glass slide. The glass slide was treated with xylene for 5 minutes three times, to thereby remove paraffin. It was then successively treated with 100%, 90%, and 70% ethanol each for 3 minutes so as to dehydrate the tumor tissue, followed by incubation in PBS for 5 minutes. The glass slide was treated with 20 μg/ml of proteinase K (SIGMA) for 15 minutes, washed with distilled water, and then, treated with 3% H2O2 (vol/vol, in PBS) for 5 minutes, to thereby inhibit the activity of endogenous peroxidase. The glass slide was treated with an equilibration buffer for 10 seconds, followed by treating with a terminus dexoynucleotidyl transferase (TdT) at 37° for 1 hour. After the reaction was completed, the glass slide was treated with a stop buffer and washed. Next, the glass slide was treated with a DAB coloring agent for 5 minutes, and counterstained with methyl green. After the staining, the glass slide was dehydrated, sealed with a cover slip, and observed with an optical microscope.
According to the results shown in
The TUNEL assay was performed according to the same method as described in Example 12 except that each of the cell permeable p18 recombinant protein (Hp18M1, HM2p18M2, HM3p18), vehicle and Hp18 (control) was administered to the mice subdivided into five groups (5 mice per group) via intratumoral injection for 14 days according to the same method as described in Example 9, and tumor tissue samples were extracted from a mouse in each group.
Referring to the results shown in
The ApopTag assay was performed according to the same method as described in Example 13 except that each of the cell permeable p18 recombinant proteins (Hp18M1, HM2p18M2, HM3p18), vehicle, and Hp18 (control) was administered to the mice subdivided into five groups (5 mice per group) via intratumoral injection for 14 days according to the same method as described in Example 9, and tumor tissue samples were extracted from a mouse in each group.
According to the results shown in
In order to examine the change in protein expression pattern in the tumor tissue treated with the cell permeable p18 recombinant protein according to the present invention, a microarray assay was performed as follows.
In particular, each of the cell permeable p18 recombinant protein (HM2p18M2), vehicle and Hp18 (control) was administered to the mice subdivided into three groups via intratumoral injection for 14 days, and then left alone for 14 days after the administration was terminated, according to the same method as described in Example 8 above. Fourteen days after the administration was terminated, tumor tissue samples were extracted from the mouse of each group and freezed with liquid nitrogen. Total RNA was isolated from the tumor tissue by using a TRIZOL reagent (INVITROGEN) according to the manufacturer's instruction, and treated with an RNase-free DNase (LIFE TECHNOLOGIES, Inc.), to thereby completely remove the remaining genomic DNA.
The thus isolated RNA was subjected to synthesis and hybridization of a target cRNA probe by using a Low RNA Input Linear Amplification kit (AGILENT TECHNOLOGY) according to the manufacturer's instruction. In brief, 1 μg of total RNA was mixed with a T7 promoter specific primer and reacted at 65° for 10 minutes. A cDNA master mix was prepared by mixing a first strand buffer (5×), 0.1 M DTT, 10 mM dNTP mix, RNase-Out and MMLV-RT (reverse transcriptase), and added to the reaction mixture. The resulting mixture was reacted at 40° C. for 2 hours, followed by reacting at 65° for 15 minutes, to thereby terminate the reverse transcription and dsDNA synthesis. A transcription master mix was prepared by mixing a transcription buffer (4×), 0.1 M DTT, NTP mix, 50% PEG, RNase-Out, inorganic pyrophosphatase, T7-RNA polymerase and cyanine (3/5-CTP) according to the manufacturer's instruction. The thus prepared transcription master mix was added to the dsDNA reaction mixture and reacted at 40° for 2 hours so as to perform dsDNA transcription. The thus amplified and labeled cRNA was purified with a cRNA Cleanup Module (AGILENT TECHNOLOGY) according to the manufacturer's instruction. The labeled target cRNA was quantified by using a ND-1000 spectrophotometer (NANODROP TECHNOLOGIES, Inc.). After the labeling efficiency was examined, cRNA was mixed with a blocking agent (10×) and a fragmentation buffer (25×), and reacted at 60° for 30 minutes so as to carry out the fragmentation of cRNA. The fragmented cRNA was resuspended in a hybridization buffer (2×) and directly dropped on a Whole Human Genome Oligo Microarray (44K). The microarray was subjected to hybridization in a hybridization oven (AGILENT TECHNOLOGY) at 65° for 17 hours, followed by washing according to the manufacturer's instruction (AGILENT TECHNOLOGY).
The hybridization pattern was read by using a DNA microarray scanner (AGILENT TECHNOLOGY) and quantified by using a Feature Extraction Software (AGILENT TECHNOLOGY). Data normalization and selection of fold-changed genes were carried out by using a Gene Spring GX 7.3 soft wear (AGILENT TECHNOLOGY). The average of the normalized ratio was calculated by dividing a normalized signal channel strength by a normalized control channel strength. Functional annotation for a gene was conducted by using a Gene Spring GX 7.3 software (AGILENT TECHNOLOGY) according to the Gene Ontology™ Consortium.
The results of the microarray analysis are summarized in
As described in Table 3 above, in case of the apoptosis-relating genes, while the expressions of protein kinase C (PRKCE), death inducer-obliteratio 1 (DIDO1), and member 8 of a tumor necrosis factor receptor superfamily (TNFRSF18) were up-regulated by 1.5- to 2.0-fold, the expression of phosphoinositide-3-kinase (PIK3R2) was down-regulated by 3-fold in the mouse group treated with the cell permeable p18 recombinant protein compared to that treated with the control protein.
As described in Tables 4a and 4b above, in case of the cell cycle regulation-relating genes, the expression of retinoblastoma binding protein 6 (RBBP6) was up-regulated by 1.8-fold in the mouse group treated with the cell permeable p18 recombinant protein compared to that treated with the control protein.
As described in Tables 5a to 5c above, in case of the cell growth-relating genes, the expressions of a member 10A (WNT10A) and a member 16A (WNT16A) of a wingless-type MMTV integration site family were down-regulated by 2- to 2.5-fold in the mouse group treated with the cell permeable p18 recombinant protein compared to that treated with the control protein.
As described in Table 6 above, in case of the cell proliferation-relating genes, the expression of CD28 was down-regulated by 4-fold in the mouse group treated with the cell permeable p18 recombinant protein compared to that treated with the control protein.
As described in Table 7 above, in case of metastasis and angiogenesis-relating genes, the expression of metastasis associated protein 1 (MTA1) was up-regulated by 2-fold in the mouse group treated with the cell permeable p18 recombinant protein compared to that treated with the control protein.
Although the invention has been described in detail for the purpose of illustration, it is understood that such detail is solely for that purpose, and variations can be made therein by those skilled in the art without departing from the spirit and scope of the invention which is defined by the following claims.
INDUSTRIAL APPLICABILITYThe cell permeable p18 recombinant proteins of the present invention can activate cell signaling mechanisms involved in the activation of ATM and p53 that induce cell cycle arrest and apoptosis in response to DNA damage or oncogenic signals by efficiently introducing a tumor suppressor p18 into a cell. Therefore, the cell permeable p18 recombinant proteins of the present invention can be effectively used as an anticancer agent for various kinds of human cancers.
Claims
1. A cell permeable p18 recombinant protein comprising:
- a macromolecule transduction domain (MTD) fused to the N-terminus or C-terminus of a tumor suppressor p18, wherein the MTD comprises SEQ ID NO: 6 or 8, and the p18 comprises SEQ ID NO: 2 or a truncation of SEQ ID NO: 2 lacking one or more of the N-, S- and C- terminal domains, wherein the N-terminal domain corresponds to amino acid residues 1-60 of SEQ ID NO:2, the S-terminal domain corresponds to amino acid residues 61-120 of SEQ ID NO:2, and the C-terminal domain corresponds to amino acid residues 121-168 of SEQ ID NO:2.
2. The cell permeable p18 recombinant protein according to claim 1, further comprising: a nuclear localization sequence (NLS) and a histidine-tag affinity domain, said nuclear localization sequence and histidine-tag affinity domain being covalently coupled to one end of the recombinant protein.
3. The cell permeable p18 recombinant protein according to claim 1, wherein the recombinant protein is selected from the group consisting of:
- a recombinant protein wherein the MTD comprises SEQ ID NO: 6 and is fused to the N-terminus of the; p18;
- a recombinant protein wherein the MTD comprises SEQ ID NO: 6 and is fused to the C-terminus of the p18;
- a recombinant protein wherein the MTD comprises SEQ ID NO: 8 and is fused to the N-terminus of the p18; and
- a recombinant protein wherein the MTD comprises SEQ ID NO: 8 and is fused to the C-terminus of the p18.
4. The cell permeable p18 recombinant protein according to claim 1, wherein the recombinant protein has an amino acid sequence selected from the group consisting of SEQ ID NOS: 42, 44, 48, and 50.
5. A polynucleotide encoding the cell permeable p18 recombinant protein according to claim 1.
6. The polynucleotide according to claim 5, wherein the polynucleotide has a nucleotide sequence selected from the group consisting of SEQ ID NOS: 41, 43, 47, and 49.
7. An expression vector comprising the polynucleotide according to claim 5.
8. The expression vector according to claim 7, wherein the expression vector is selected from the group consisting pHM2p18, pHp18M2, pHM3p18, and pHp18M3.
9. A transformant comprising the expression vector according to claim 7.
10. The transformant according to claim 9, wherein the transformant is E. coil DH5α/HM3p18 (Accession No. KCTC-11312BP).
11. A method of producing a cell permeable p18 recombinant protein comprising culturing the transformant according to claim 9.
12. A pharmaceutical composition for treating p18 deficiency or failure comprising the cell permeable p18 recombinant protein according to claim 1 as an effective ingredient and a pharmaceutically acceptable carrier.
13. A cell permeable p18 recombinant protein comprising a first MTD fused to the N-terminus of a human tumor suppressor p18 and a second MTD fused to the C-terminus of said human tumor p18 suppressor, wherein the first and second MTDs independently comprise SEQ ID NO: 6 or 8 and the p18 comprises SEQ ID NO: 2.
14. The cell permeable p18 recombinant protein of claim 13 wherein the first and second MTDs comprises SEQ ID NO 6 or SEQ ID NO:8.
15. The cell permeable p18 recombinant protein according to claim 13, wherein the recombinant protein has an amino acid sequence of SEQ ID NO: 46 or SEQ ID NO: 52.
16. A polynucleotide encoding the cell permeable p18 recombinant protein according to claim 13.
17. The polynucleotide according to claim 16, wherein the polynucleotide has a nucleotide sequence of SEQ ID NO: 45 or SEQ ID NO:51.
18. An expression vector comprising the polynucleotide according to claim 16.
19. The expression vector according to claim 18, wherein the expression vector is pHM2p18M2 or pHM3p18M3.
20. A transformant comprising the expression vector according to claim 18.
21. The transformant according to claim 19, wherein the transformant is E. coli DH5α/HM2p18M2 (Accession No. KCTC- 11311BP).
22. The cell permeable p18 recombinant protein according to claim 13, further comprising: a nuclear localization sequence (NLS) and a histidine-tag affinity domain, said nuclear localization sequence and histidine-tag affinity domain being covalently coupled to one end of the recombinant protein.
23. A method of producing a cell permeable p18 recombinant protein comprising culturing the transformant according to claims 20.
24. A pharmaceutical composition for treating p18 deficiency or failure comprising the cell permeable p18 recombinant protein according to claim 13 as an effective ingredient and a pharmaceutically acceptable carrier.
| 20040172684 | September 2, 2004 | Kovalic et al. |
| WO 95/34295 | December 1995 | WO |
- UniProtKB/TrEMBL Accession No. C2HMP7, accessed at http://www.uniprot.org/uniprot/C2HMP7, Feb. 8, 2013.
- Extended European Search Report issued Jan. 17, 2012, in Patent Application No. 08828990.5.
- Marie A. Bogoyevitch, et al., “Taking the Cell by Stealth or Storm? Protein Transduction Domains (PTDs) as Versatile Vectors for Delivery”, DNA and Cell Biology, vol. 21, No. 12, XP 1145670, 2002, pp. 879-894.
- Bryan R. Meade, et al., “Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides”, Advanced Drug Delivery Reviews, vol. 59, 2007, pp. 134-140.
- Martha Schreiber, et al., “Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21WAF1/CIP1, and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity”, Oncogene, vol. 18(9), Mar. 4, 1999, pp. 1663-1676.
- Hiroshi Harada, et al., “Antitumor Protein Therapy; Application of the Protein Transduction Domain to the Development of a Protein Drug for Cancer Treatment”, Breast Cancer, vol. 13, No. 1, Jan. 2006, pp. 16-26.
- Mike S. S. Chang, et al., “Dissecting Intracellular Signaling Pathways with Membrane-Permeable Peptides”, Science's STKE, vol. 2000 (47), pl. 1, Aug. 29, 2000, pp. 1-10 and cover page.
- Anne Scheller, et al., “Evidence for an amphipathicity independent cellular uptake of amphipathic cell-penetrating peptides”, European Journal Biochemistry, vol. 267, 2000, pp. 6043-6049.
- Jacek Hawiger, “Noninvasive intracellular delivery of functional peptides and proteins”, Current Opinion in Chemical Biology, vol. 3(1), Feb. 1999, pp. 89-94.
- D. G. De Rooji, et al. “Regulation of Spermatogonial Proliferation”, Annals New York Academy of Sciences 564, The Seminiferous Tubule, Part V, 1989, pp. 140-153.
- Jayne M. Stommel, et al., “A New Twist in the Feedback Loop; Stress-Activated MDM2 Destabilization is Required for p53 Activation”, Cell Cycle, vol. 4, Issue 3, Mar. 2005, pp. 411-417.
- Yunyuan V. Wang, et al., “Quantitative analyses reveal the importance of regulated Hdmx degradation for p53 activation”, PNAS, vol. 104, No. 30, Jul. 24, 2007, pp. 12365-12370.
- Xiantao Wang, et al., “p27Kip1 overexpression causes apoptotic death of mammalian cells”, Oncogene (1997) 15, pages 2991-2997.
- Feng Bai, et al., “Haploinsufficiency of p18INK4C Sensitizes Mice to Carcinogen-Induced Tumorigenesis”, Molecular and Cellular Biology, vol. 23, No. 4, Feb. 2003, pp. 1269-1277.
- David A. Alcorta, et al., “Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts”, Proc. Natl. Acad. Sci. Biochemistry, vol. 93, Nov. 1996, pp. 13742-13747.
- Thenaa K. Said, et al., “Interaction of Retinoblastoma Protein and D Cyclins During Cell-Growth Inhibition by Hexamethylenebisacetamide in TM2H Mouse Epithelial Cells”, Molecular Carcinogenesis, 22, 1998, pp. 128-143.
- Junan Li, et al., “Tumor Suppressor INK4: Determination of the Solution Structure of p18INK4C and Demonstration of the Functional Significance of Loops in p18INK4C and p16INK4A”, Biochemistry, 38, 1999, pp. 2930-2940.
- Michael B. Kastan, “Checkin two steps”, Nature, vol. 410, Apr. 12, 2001, pp. 766-767.
- Daewoong Jo, et al., “Epigenetic regulation of gene structure and function with a cell-permeable Cre recombinase”, Research Article, Nature Biotechnology, vol. 19, Oct. 2001, pp. 929-933.
- Dimitrios Balomenos, et al., “Cell-cycle regulation in immunity, tolerance and autoimmunity”, Viewpoint, Immunology Today, vol. 21, No. 11, Nov. 2000, pp. 551-555.
- Shu Lu, et al., “Atm-haploinsufficiency enhances susceptibility to carcinogen-induced mammary tumors”, Carcinogenesis, vol. 27, No. 4, 2006, pp. 848-855.
- Robert T. Abraham, “Part-time cop nabs deviant DNA”, Nature Medicine, News and Views, vol. 11, No. 3, Mar. 2005, pp. 257-258.
- Bum-Joon Park, et al., “The haploinsufficient Tumor Suppressor p18 Upregulates p53 via Interactions with ATM/ATR”, Cell, vol. 120, Jan. 28, 2005, pp. 209-221.
- John E. French, et al., “Loss of heterozygosity frequency at the Trp53 locus in p53-deficient (+/−) mouse tumors is carcinogen- and tissue-dependent”, Carcinogenesis, vol. 21, No. 1, 2001, pp. 99-106.
- Fumio Ide, et al., “p53 Haploinsufficiency Profoundly Accelerates the Onset of Tongue Tumors in Mice Lacking the Xeroderma Pigmentosum Group A Gene”, American Journal of Pathology, Short Communication, vol. 163, No. 5, Nov. 2003, pp. 1729-1733.
- Anne K. Baumgärtner, et al., “High Frequency of Genetic Aberrations in Enteropathy-Type T-Cell Lymphoma”, Laboratory Investigation, vol. 83, No. 10, Oct. 2003, pp. 1509-1516.
- Kinneret Savitsky, et al., “The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species”, Human Molecular Genetics, vol. 4, No. 11, 1995, pp. 2025-2032.
- James Turkson, et al., “Novel peptidomimetic inhibitors of Signal transducer and activator of transcription 3 dimerization and biological activity”, Molecular Cancer Therapeutics, No. 3, Mar. 16, 2004, pp. 261-269.
- Rolfs A, et al., “cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) [synthetic construct]”, Synthetic Construct, GenBank Accession No. ABM85633, Mar. 10, 2008, 3 pages.
Type: Grant
Filed: Sep 4, 2008
Date of Patent: May 21, 2013
Patent Publication Number: 20100305041
Assignee: Procell Therapeutics Inc. (Seoul)
Inventors: Daewoong Jo (Seoul), Seolhwa Kim (Gwangju), Jung-Hee Lim (Seoul), Kisuk Park (Seoul), Se-Eun Kang (Busan)
Primary Examiner: Christina Bradley
Assistant Examiner: Kristina M Hellman
Application Number: 12/676,491
International Classification: C12N 15/62 (20060101);
